This is a working overview of Angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-02. Anything still debated is marked as such rather than presented as settled.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
== External links == Anorectics at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Mitchell, Kari (January 1997). "Anorexiant Agents: Considerations for Use" (PDF). Drug Therapy Topics. University of Washington Medical Center. Archived from the original (PDF) on 2013-12-26. Retrieved 25 December 2013.
Thus, the ability of low doses of trazodone to improve sleep in depressed patients may be an important mechanism whereby trazodone can augment the efficacy of other antidepressants. Trazodone's potent α1-adrenergic blockade may cause some side effects like orthostatic hypotension and sedation. Conversely, along with 5-HT2A and H1 receptor antagonism, it may contribute to its efficacy as a hypnotic. Trazodone lacks any affinity for the muscarinic acetylcholine receptors, so does not produce anticholinergic side effects. mCPP, a non-selective serotonin receptor modulator and serotonin releasing agent, is an active metabolite of trazodone and has been suggested to possibly play a role in its therapeutic benefits. However, research has not supported this hypothesis and mCPP might actually antagonize the efficacy of trazodone as well as produce additional side effects.
is known as the specificity constant, which gives a measure of the affinity of a substrate to some particular enzyme. Also known as the efficiency of an enzyme, this relationship reveals an enzyme's preference for a particular substrate. The higher the specificity constant of an enzyme corresponds to a high preference for that substrate.
Mazda's automotive plans for the early sixties consisted of growing alongside the Japanese economy. To achieve this goal, they began by building an extremely affordable kei car, the R360 in 1960, planning on introducing gradually larger and pricier cars as the Japanese customers became able to afford them. As a preview, testing the waters, a larger "Mazda 700" prototype was shown at the eighth Tokyo Motor Show in 1961, and formed the basis for the upcoming Mazda Familia. Meanwhile, the four door version of the R360 was introduced as the Mazda Carol, which appeared in 1962, and discontinued in 1964. The first production Familia, styled by a young Giorgetto Giugiaro while working at Carrozzeria Bertone, appeared in October 1963. In line with Mazda's policy of only gradually approaching the production of private cars (a luxury in Japan at the time), the first Familia was initially only available as a commercial two-door wagon called the Familia van. The van was joined in April 1964 by a plusher Familia wagon, in October by a four-door saloon, and in November by a two-door saloon. The "flat deck" design of the saloon versions was reportedly inspired by the Chevrolet Corvair. Private car versions received foglights in the grille as well as more chrome trim. The Familia was sold in other markets as the 800. The Familia was introduced to the Japanese market in time for the 1964 Summer Olympics which began in October. The cars used a 782 cc, "SA" four-stroke aluminum straight-four engine, also known as the "white engine".
=== Greg Grayson === Greg Grayson (Ben Lloyd-Hughes) is a VP on Pierpoint's CPS desk. He is initially romantically interested in Harper; she rejects his advances, but the two remain friends afterwards. Greg copes with Pierpoint's ruthless culture using drugs, and also explores writing in his spare time, which Eric publicly mocks him for. During an office Christmas party, Harper tells Robert to look after Greg and make sure he stays sober, but Robert and Greg end up indulging in heavy drug use with a client, culminating in Greg running headfirst into a window and injuring himself. Greg leaves Pierpoint after the incident. In series 2 it is revealed that Greg has had a book published. Greg briefly reappears at the end of series 3, now working as a venture capital investor in California. He listens to a sales pitch from Robert for Little Labs, a startup producing medicinal psilocybin.
Sources: en.wikipedia.org
== Metabolism == Vitexin beta-glucosyltransferase is an enzyme characterised from Silene alba that converts vitexin to its 2"-O-β-D-glucoside (flavosativaside) using UDP-glucose as the source of the added glucose unit.
The gold in the county council's coat of arms symbolises the wealth of the area. Black is for both mining and the Black Mountains. The fountain is a medieval heraldic charge displayed as a roundel barry wavy argent and azure. It represents water and refers to both the water catchment area and the rivers and lakes. Thus, the arms contain references to the hills and mountains, rivers and lakes, water supply and industry. The crest continues the colouring of the arms. A tower has been used in preference to a mural crown, which alludes to the county's military history and remains. From the tower rises a red kite, a bird almost extinct elsewhere in Britain but thriving in Powys. The bird is a "semé of black lozenges" for the former coal mining industry, while the golden fleece it carries is a reference to the importance of sheep rearing in the county. The county motto is: Powys – the paradise of Wales (Welsh: Powys Paradwys Cymru).
After a memorable 90th birthday, at which she was surrounded by her now vast family, Zita's habitually-robust health began to fail. She developed inoperable cataracts in both eyes. Her last major family gathering took place at Zizers, in 1987, when her children and grandchildren joined in celebrating her 95th birthday. While visiting her daughter, in summer 1988, she developed pneumonia and spent most of the autumn and winter bedridden. Finally, she called Otto in early March 1989 and told him she was dying. He and the rest of the family travelled to her bedside and took turns keeping her company until she died in the early hours of 14 March 1989. She was 96 years old, and was the last surviving child of Robert, Duke of Parma from both his marriages. Her funeral was held in Vienna on 1 April. The government allowed it to take place on Austrian soil if the cost was borne by the Habsburgs themselves. Zita's body was carried to the Imperial Crypt under Capuchin Church in the same funeral coach she had walked behind during the funeral of Emperor Franz Joseph in 1916. It was attended by over 200 members of the Habsburg and Bourbon-Parma families, and the service had 6,000 attendees including leading politicians, state officials and international representatives, including a representative of Pope John Paul II. Following an ancient custom, the Empress had asked that her heart, which was placed in an urn, stay behind at Muri Abbey, in Switzerland, where the Emperor's heart had rested for decades.
In 1916, Grace acquired a controlling interest in the Pacific Mail Steamship Company. In 1921, Pacific received five 535 ft. President class ships from the United States Shipping Board for transpacific operation. In 1923, the US Shipping board decided to place the five ships up for bid and Dollar Shipping Company won the bid. With no large ships for the transpacific operations, Grace sold the Pacific Mail, its registered name, and goodwill to Dollar. Now without a transpacific service, Grace did not need the six intercoastal freighters and sold them to the American Hawaiian Line. At this time, Grace formed the Panama Mail Steamship Company, to operate the smaller ships that were formerly owned and used by the Pacific Mail in the Central American trade. These ships were not involved in the sale to Dollar. On the death of William R. Grace in 1904, he was succeeded by William L. Sauders as company president followed by Joseph Peter Grace Sr. (1872–1950) who became president in 1907. In 1938, the Colombian Line merged with Grace Line bringing an end to the Colombian Line. During World War II, Grace Lines operated transport for the U.S. War Shipping Administration, including the SS Sea Marlin. J. Peter Grace took over management of the company after his father suffered a stroke in 1945. After the war, the Grace line operated 23 ships totaling 188,000 gross tons, and 14 more on bareboat charters.
At first, some major cities or capitals formed local Juntas on the basis of laws from the Hispanic tradition. The armed conflicts started in 1809, with short-lived juntas established to govern in Chuquisaca, La Paz and Quito opposing the government of the Supreme Central Junta of Seville. Although various regions objected to many crown policies, "there was little interest in outright independence; indeed there was widespread support for the Spanish Central Junta formed to lead the resistance against the French". While some Spanish Americans believed that independence was necessary, most who initially supported the creation of the new governments saw them as a means to preserve the region's autonomy from the French. Although there had been research on the idea of a separate Spanish American ("creole") identity separate from that of Iberia, political independence was not initially the aim of most Spanish Americans, nor was it necessarily inevitable. French forces had taken over southern Spain and forced the Supreme Junta to seek refuge in the island-city of Cádiz. The escape to Cádiz and the dissolution of the Supreme Central Junta on 29 January 1810, because of the reverses suffered after the Battle of Ocaña by the Spanish forces paid with Spanish American money, set off another wave of juntas being established in the Americas. These juntas gained their own levels of independence and autonomy from Spain through declarations in 1808–1810.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.